Study Reveals Previously Unknown Drug-Associated Arrhythmias
To identify medications with potential proarrhythmic association.
CHF and Arrhythmias
MPR Weekly Dose Podcast Episode 65
On this week’s MPR pod we take a look at the current status of Johnson & Johnson’s COVID-19 vaccine candidate; Considerations in assessing blood donors during pandemic times; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.
Verquvo Approved for Heart Failure with Reduced Ejection Fraction
The approval was based on data from the double-blind, placebo-controlled phase 3 VICTORIA trial.
Empagliflozin Under Review for Heart Failure with Reduced Ejection Fraction
The sNDA is supported by data from the phase 3 EMPEROR-Reduced trial which compared the efficacy and safety of empagliflozin to placebo, in addition to recommended therapy, in 3730 patients with chronic heart failure with reduced ejection fraction.
FDA Panel Votes on Entresto for HF With Preserved Ejection Fraction
The recommendation was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial.
Glucosamine Supplement Tied to Lower Mortality
Regular use tied to a 65% risk for cardiovascular death
MPR Weekly Dose Podcast Episode 61
This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has its approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.
USPSTF Urges Behavioral Counseling to Reduce CVD Risk
Behavioral counseling interventions to promote healthy diet and physical activity have moderate net benefit
Higher Levothyroxine Doses Linked to Afib in Older Patients
To evaluate the association, the study authors utilized healthcare databases from Ontario, Canada to identify adults 66 years of age and older with no history of AF who filled at least 1 prescription for levothyroxine.
Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.
